In the News
Clinical trials in India – Changing regulatory environment - by Dr. Chetan Tamhankar (Head -Clinical Development Services)
Pharmabiz-01/02/2017. The recent regulatory and policy changes announced by the government has once again made clinical trials in India lucrative for the global healthcare industry.
Syngene International Q3 net profit up 11.54% at Rs 74 cr
Outlook-24/01/2017. We made good progress on client service delivery across all of business verticals despite a fire incident damaging one of our research facilities, effective implementation of our business continuity plan..
Syngene International: Discover the chemistry
The Hindu Businessline-30/10/2016. From a pure play research services company, catering to the research needs of innovative pharma companies, Syngene is now repositioning itself as a fully integrated contract research and manufacturing company.
Syngene posts 55% rise in net profit
Live Mint-20/10/2016. Profit rose to Rs75 crore in the second quarter, from Rs48 crore a year earlier. Revenue rose 22% increase to Rs.319 crore from Rs.262 crore...
Syngene International acquires Strand Life Sciences’s assets.
Live Mint-22/09/2016. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities...
Syngene International Commissions Dedicated R&D Center for Amgen.
Financial Times-06/09/2016. The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines...
Syngene Posts 28% Rise In Q1 Profit
Profit NDTV-21/07/2016. Standalone total income from operations also rose to Rs 274.5 crore for the quarter ended June, 2016 as against Rs 233.7 crore for the year-ago..
Syngene Q4 profit up 18% to Rs 66 crore
Mint-27/04/2016. The profit was notched up on a 28% increase in Syngene’s revenue to Rs334 crore from Rs254 crore
Syngene Q3 profit jumps 31% to Rs 59 cr.
Business Standard-21/01/2016. Syngene reported a 31% jump in third quarter profits to Rs 59 crore and 23% growth in revenues to Rs 281 crore on improved business from its global clients to help build new drug discovery.
India has 'natural potential to grow' in CRO space, says Syngene CEO
Outsourcing Pharma-14/01/2016. An exclusive interview with Peter Bains- CEO ,Syngene International Ltd -